[Prostate cancer at high risk of recurrence: results of 12 months of radiotherapy-hormone therapy].
OBJECTIVE
To evaluate the risk of progression after conformal radiotherapy combined with 12 months of adjuvant hormone therapy in a series of patients with prostate cancer considered to be at high risk of progression.


METHODS
Between January 1997 and December 2001, 63 consecutive patients classified at high-risk according to Amico's classification were treated by combined radiotherapy-hormone therapy. All patients presented at least one factor of the high-risk group of Amico's classification: TNM 92 stage T2c, T3 or T4, or Gleason score > or = 8 or baseline PSA > 20 ng/ml. All patients were treated by combined radiotherapy-hormone therapy with concomitant hormone therapy for 2 months and adjuvant hormone therapy for 10 months. Biochemical progression was defined according to the ASTRO criteria. The median follow-up was 36 months.


RESULTS
The 3-year and 5-year biochemical recurrence-free survival was 78%. No local recurrence was observed in 94% of cases and no metastases were observed in 93% of patients. On univariate analysis, only a baseline PSA greater than 22 ng/ml was identified as a predictive factor of early biochemical recurrence. The 3-year biochemical recurrence-free survival was 96% for patients with baseline PSA < 22 ng/ml and 56% for patients with baseline PSA > or = 22 ng/ml (p=0.0017).


CONCLUSIONS
The early results of 12 months of radiotherapy-hormone therapy in high-risk patients in our series were comparable to those reported in the literature. Only a high baseline PSA was predictive of early biochemical recurrence. Adjuvant hormone therapy (long-term, intermittent hormone therapy) could therefore be modulated as a function of the baseline PSA.
Service d'Urologie, Hôpital Salvator Marseille, France.
Véronique
V
Delaporte
Xavier
X
Muracciole
Eric
E
Lechevallier
Cyrille
C
Bastide
Didier
D
Cowen
Dominique
D
Rossi
Christian
C
Coulange
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D012307:Risk Factors
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone